Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN protocol

British Journal of Dermatology

Volumn 162, Issue 4, 2010, Pages 860-865

  De Sica Chapman, A ^a   Williams, G ^b   Soni, N ^b   Bunker, C B ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Granulocyte colony stimulating factor; Re epithelialization; Toxic epidermal necrolysis

Indexed keywords

ALBUMIN; CEFUROXIME; CYCLOSPORIN A; IMMUNOGLOBULIN; PHENOBARBITAL; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE; TEICOPLANIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CASE REPORT; CHEST INFECTION; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG MEGADOSE; DRUG WITHDRAWAL; EPILEPTIC STATE; EPITHELIZATION; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPOTHERMIA; KIDNEY FAILURE; MALE; NEUTROPENIA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SEPTICEMIA; SKIN BIOPSY; TOXIC EPIDERMAL NECROLYSIS; MIDDLE AGED; PHYSIOLOGY; PRACTICE GUIDELINE; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME; UNITED KINGDOM; WOUND HEALING;

FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LONDON; MALE; MIDDLE AGED; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME; WOUND HEALING;

EID: 77949862183     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09585.x     Document Type: Article

References (23)

1. Dalli RL, Kumar R, Kennedy P et al. Toxic epidermal necrolysis/Stevens- Johnson syndrome: current trends in management. ANZ J Surg 2007 77 : 671 676.
2. Herndon DN. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995 180 : 340 342.
3. Chave TA, Mortimer NJ, Sladden MJ et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005 153 : 241 253.
4. Fromowitz JS, Ramos-Caro FA, Flowers FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 2007 46 : 1092 1094.
5. Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res 2008 29 : 706 712.
6. Paquet P, Jacob E, Quatresooz P et al. Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns 2007 33 : 100 104.
7. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006 6 : 543 549.
8. French LE, Tschopp J. Protein-based therapeutic approaches targeting death receptors. Cell Death Differ 2003 10 : 117 123.
9. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 282 : 490 493.
10. Paquet P, Kaveri S, Jacob E et al. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 2006 15 : 381 386.
11. Reipert BM, Stellamor MT, Poell M et al. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang 2008 94 : 334 341.
12. Liu J, Sakane T, Tsunematsu T. The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6. Int Arch Allergy Immunol 1992 98 : 293 298.
13. Li M, Zhang H, Yang J et al. Inhibitory effect of cyclosporin A on T lymphocyte DNA synthesis. J Tongji Med Univ 1992 12 : 39 42.
14. Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008 14 : 1343 1350.
15. Paquet P, Jacob E, Damas P et al. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 2005 297 : 266 273.
16. Cianfarani F, Tommasi R, Failla CM et al. Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. Br J Dermatol 2006 154 : 34 41.
17. Evans AV, Atherton DJ. Recalcitrant ulcers in necrobiosis lipoidica diabeticorum healed by topical granulocyte-macrophage colony-stimulating factor. Br J Dermatol 2002 147 : 1023 1025.
18. Fang Y, Gong SJ, Xu YH et al. Impaired cutaneous wound healing in granulocyte/macrophage colony-stimulating factor knockout mice. Br J Dermatol 2007 157 : 458 465.
19. Rutella S, Zavala F, Danese S et al. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 2005 175 : 7085 7091.
20. Vela-Ojeda J, Esparza MA, Reyes-Maldonado E et al. CD4+ CD25+ lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors. Stem Cells Dev 2005 14 : 310 316.
21. Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol 2008 158 : 1230 1238.
22. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006 135 : 651 652.
23. Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008 58 : 33 40.